NasdaqGS:ONCBiotechs
Is It Time To Reassess BeOne Medicines (ONC) After Its 61% One-Year Share Price Gain?
If you are wondering whether BeOne Medicines at US$338.19 is offering fair value or a potential mispricing, the starting point is to look closely at what the market is paying for the business today.
The share price performance has been mixed across time frames, with returns of 0.1% over 7 days, 7.0% over 30 days, 8.7% year to date, 61.0% over 1 year, 26.9% over 3 years and a 9.7% decline over 5 years.
Recent attention on BeOne Medicines has been reflected in these moves, with investors...